These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34859049)

  • 1. An Integrative Pan-Cancer Analysis of PBK in Human Tumors.
    Wen H; Chen Z; Li M; Huang Q; Deng Y; Zheng J; Xiong M; Wang P; Zhang W
    Front Mol Biosci; 2021; 8():755911. PubMed ID: 34859049
    [No Abstract]   [Full Text] [Related]  

  • 2. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omics- and Pharmacogenomic Evidence for the Prognostic, Regulatory, and Immune-Related Roles of PBK in a Pan-Cancer Cohort.
    Liu Y; Xiang J; Peng G; Shen C
    Front Mol Biosci; 2021; 8():785370. PubMed ID: 34859058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDZ Binding Kinase/T-LAK Cell-Derived Protein Kinase Plays an Oncogenic Role and Promotes Immune Escape in Human Tumors.
    Feng T; Zhang Y; Ling S; Xu C; Lyu Y; Lu T; Liu X; Ying L; Wan Y; Zhong H; Su D
    J Oncol; 2021; 2021():8892479. PubMed ID: 34603451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 6. PBK correlates with prognosis, immune escape and drug response in LUAD.
    Ma H; Zhang J; Shi Y; Wang Z; Nie W; Cai J; Huang Y; Liu B; Wang X; Lian C
    Sci Rep; 2023 Nov; 13(1):20452. PubMed ID: 37993518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 8. A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective.
    Bao H; Luo Y; Ding G; Fu Z
    J Oncol; 2022; 2022():3982539. PubMed ID: 35578600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.
    Lv Z; Qi L; Hu X; Mo M; Jiang H; Fan B; Li Y
    Front Mol Biosci; 2021; 8():631067. PubMed ID: 33665207
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.
    Li L; Huang Z; Du K; Liu X; Li C; Wang D; Zhang Y; Wang C; Li J
    Front Pharmacol; 2022; 13():900699. PubMed ID: 35668930
    [No Abstract]   [Full Text] [Related]  

  • 13. PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
    Lee DH; Jeong YJ; Won JY; Sim HI; Park Y; Jin HS
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrative Pan-Cancer Analysis Revealing LCN2 as an Oncogenic Immune Protein in Tumor Microenvironment.
    Xu WX; Zhang J; Hua YT; Yang SJ; Wang DD; Tang JH
    Front Oncol; 2020; 10():605097. PubMed ID: 33425761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
    Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
    Front Genet; 2022; 13():938510. PubMed ID: 36171879
    [No Abstract]   [Full Text] [Related]  

  • 17. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIF18B is a Prognostic Biomarker and Correlates with Immune Infiltrates in Pan-Cancer.
    Qiu MJ; Wang QS; Li QT; Zhu LS; Li YN; Yang SL; Xiong ZF
    Front Mol Biosci; 2021; 8():559800. PubMed ID: 34109209
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
    Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
    Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.